Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2014-09-30
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Zero Positive End-expiratory Pressure Before Emergence Prevents Postoperative Atelectasis.
NCT03351946
Peroperative Use of Positive End-expiratory Pressure Prevents Formation of Atelectasis as Studied by Computerised Tomography at End of Surgery
NCT02548416
Lung Atelectasis Improvement Through Positive End Expiratory Pressure During Anesthetic Induction
NCT06900426
High-flow Nasal Oxygenation During Preoxygenation and Atelectasis
NCT06205212
End-Expiratory Lung Volume in Children Awakening From Propofol Anesthesia
NCT05821114
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group, conventional ventilatory settings
Handling of the airway during induction and intubation is performed in a conventional manner.
Initial ventilatory settings are also done in a conventional manner.
Control group, conventional ventilatory settings
Handling of the airway during induction and intubation is performed in a conventional manner.
Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.
Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
High fresh gas flow, high minute ventilation
Handling of the airway during induction and intubation is performed in a conventional manner.
Immediately after confirming a successful intubation the effect of preoxygenation is eliminated with an anti-preoxygenation maneuver.
High fresh gas flow, high minute ventilation
Handling of the airway during induction and intubation is performed in a conventional manner.
Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.
Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Control group, conventional ventilatory settings
Handling of the airway during induction and intubation is performed in a conventional manner.
Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.
Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
High fresh gas flow, high minute ventilation
Handling of the airway during induction and intubation is performed in a conventional manner.
Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI \>25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.
Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients scheduled for orthopaedic day case surgery in general anaesthesia
Exclusion Criteria
* Body Mass Index (BMI) 30 or higher
* Arterial oxygen saturation (SpO2) \<94% breathing air
* Chronic Obstructive Pulmonary Disease (COPD)
* Ischemic heart disease
* Haemoglobin \<100g/L
* Known or anticipated difficult airway and/or intubation
* Active smokers and ex-smokers with a history of more than 6 pack years
* Need for interscalene or supraclavicular regional anaesthesia with risk of phrenic nerve paralysis
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Region Västmanland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Erland Ostberg
M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mats Enlund, MD, PhD
Role: STUDY_CHAIR
Landstinget i Värmland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Landstinget Västmanland
Köping, Västmanland County, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Dnr 2012/335
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.